In Vitro Cytokine Production by HLA-B8, DR3 Positive Subjects

References

• van Rood JJ, van Hoff JP, Keuning J J. Disease predisposition, immune responsiveness and the fine structure of the HLA supergene. Transplant Rev 1975; 22: 75–90
   PubMedGoogle Scholar
• Dausset J, Contu L. The MHC and immune response in man. Immunology 80. Progress in Immunology, M Fogerau, J Dausset. Academic Press, London 1980; 513–529
   Google Scholar
• French MAH, Dawkins RL. Central MHC genes, IgA deficiency and autoimmune disease. Immunol Today 1990; 11: 271–274
   PubMedGoogle Scholar
• Amer A, Singh G. Darke C, Dolby AE. Impaired lymphocyte responsiveness to phytohaemagglutinin associated with the possession of HLA-B8.DR3. Tissue Antigens 1986; 28: 193–198
   PubMedGoogle Scholar
• Hashimoto S, McCombs CC, Michalski JP. Mechanism of a lymphocyte abnormality associated with HLA-B8.DR3 in clinically healthy individuals. Clin Exp Immunol 1989; 76: 317–323
   PubMedGoogle Scholar
• Hashimoto S, Michalski JP, Berman MA, McCombs C. Mechanism of a lymphocyte abnormality associated with HLA-B8, DR3; role of interleukin-1. Clin Exp Immunol 1990; 79: 227–232
   PubMedGoogle Scholar
• Modica MA, Cammarata G, Caruso C. HLA-B8, DR3 phe-notype and lymphocyte responses to phytohaemagglutinin. J Immunogenet 1990; 17: 101–107
   PubMedGoogle Scholar
• Candore G, Colucci AT, Modica MA. Caruso HLA-B8, DR3 T cell impairment is completely restored by in vitro treatment with interleukin-2. Immunopharmacol Im-munotoxicol 1991; 13: 551–561
   PubMed Web of Science ®Google Scholar
• Modica MA, Colucci AT, Candore G, Caruso C. The HLA-B8, DR3 haplotype and immune response in healthy subjects. Immunol Infectious Dis 1993; 3: 119–127
   Google Scholar
• Durum SK, Schmidt JA, Oppenhelm JD. Interleukin-1: an immunological perspective. Annu Rev Immunol 1985; 3: 263–287
   PubMed Web of Science ®Google Scholar
• Smith K. Interleukin-2. Annu Rev Immunol 1984; 2: 319–333
   PubMed Web of Science ®Google Scholar
• Caruso C, Candore G, Cigna D, Colucci AT, Modica MA. Biological significance of soluble IL-2 receptor. Mediators of inflammation 1993; 2: 3–21
   PubMed Web of Science ®Google Scholar
• Moller G. Gamma Interferon. Immunol Rev 1987; 97: 5–65
   PubMedGoogle Scholar
• Paul WE, Ohara J. B-Cell stimulatory factor-1/interleukin 4. Annu Rev Immunol 1987; 5: 429–459
   PubMed Web of Science ®Google Scholar
• van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990; 8: 253–278
   PubMed Web of Science ®Google Scholar
• Giordano C, Caruso C, Pantó F, Modica MA, Zambito AM, Amato MP, Galluzzo A. Dissociated production of interleukin-2 and immune gamma-interferon by phytohe-moagglutinin stimulated peripheral mononuclear cell in type I (insulin-dipendent) diabetes. J Clin Lab Immunol 1988; 27: 73–76
   PubMedGoogle Scholar
• Giordano C, Pantó F. Caruso C, Modica MA, Zambito MA. Sapienza N, Amato MP, Galluzzo A. Interleukin-2 and soluble interleukin 2-receptor secretion defect in vitro in newly diagnosed type I diabetic patients. Diabetes 1989; 38: 310–315
   PubMedGoogle Scholar
• Skurkovich S, Skurkovich B, Bellanti JA. A unifying model of the immunoregulatory role of the interferon system: can interferon produce disease in humans?. Clin Immunol Im-munopathol 1987; 43: 362–373
   PubMedGoogle Scholar
• Bendtzen K. Immune hormones (cytokines): pathogenic role in autoimmune rheumatic and endocrine diseases. Autoimmunity 1989; 2: 177–182
   PubMed Web of Science ®Google Scholar
• Jacob CO. Cytokines and anti-cytokines. Curr Opin immunol 1989; 2: 249–257
   PubMedGoogle Scholar
• Kroemer G, Martinez-A C. Cytokines and autoimmune disease. Clin Immunol Immunopathol 1991; 61: 275–295
   PubMedGoogle Scholar
• Kroemer G, Andreu JL, Gonzalo A, Gutier rez-Ramos JC, Martinez-A C. Interleukin-2, autotolerace, and autoimmunity. Adv Immunol 1991; 50: 147–235
   PubMed Web of Science ®Google Scholar
• Linker-Israeli M. Cytokine abnormalities in human lupus. Cin Immunol Immunopathol 1992; 63: 10–12
   PubMedGoogle Scholar
• Yoshizaki K, Kuritani T, Kisimoto T. Interleukin-6 in autoimmune disorders. Seminars in immunology. 1992; 4: 155–166
   PubMedGoogle Scholar
• Caruso C, Modica MA, Salerno A. Reduced rate of interleukin 2 (IL-2) production in vitro in the B8.DR3 haplotype. XVII Congr Soc It Patol. Roma-Viterbo 1986; 270–272
   Google Scholar
• Modica MA, Zambito AM, Candore G, Caruso C. Markers of T lymphocyte activaton in HLA-B8.DR3 positive subjects. Immunobiolgy 1990; 181: 257–266
   PubMedGoogle Scholar
• Modica MA, Di Lorenzo G., Galluzzo A, Giordano C, Portelli MR, Candore G, Caruso C. Soluble interleukin-2 receptor secretion defect in vitro in HLA-B8.DR3 positive sbjects. Autoimmunity 1990; 7: 87–96
   PubMed Web of Science ®Google Scholar
• Caruso C, Candore G, Colucci AT, Modica MA, Salerno A. In vitro cytokine production in HLA-B8, DR3 positive subjects. 5th Eur Histocomp Conf. Leiden (abstract) 1991
   Google Scholar
• Degli-Esposti MA, Leaver AL, Christiansen FT, Witt CS, Abraham LJ, Dawkins RL. Ancestral Haplotypes: Conserved Population MHC Haplotypes. Human Immunol 1992; 34: 242–252
   PubMed Web of Science ®Google Scholar
• Alper CA, Awdeh AZ, Yunis EJ. Conserved, Extended MHC haplotypes. Exp Clin Immunogenet 1992; 9: 58–71
   PubMedGoogle Scholar
• Caruso C, Di Lorenzo G., Modica MA, Candore G, Portelli MR, Crescimanno G, Ingrassia A, Barbagallo-Sangiorgi G, Salerno A. Soluble interleukin-2 receptor release defect in vitro in elderly subjects. Mech Ageing Develop 1991; 59: 27–35
   PubMedGoogle Scholar
• Candore G, Di Lorenzo G., Melluso M, Cigna D, Colucci AT, Modica MA, Caruso C. γ-interferon, interleukin-4 and interleukin-6 in vitro production in old subjects. Autoimmunity 1993; 16: 275–280
   PubMed Web of Science ®Google Scholar
• Hannet I, Erkeller-Yuksel F, Lydyard P, Deneys V, DeBruy-Ere M. Developmental and maturational changes in human blood lymphocyte subpopulations. Immunol Today 1992; 13: 215–218
   PubMedGoogle Scholar
• Vilcek J. Henriksen-Desterfano D, Siegel D, Klion A, Robb RJ, Le J, Regulation of IFN-γ induction in human peripheral blood cells by exogenous and endogenously produced interleukin-2. J Immunol 1985; 135: 1851–1856
   PubMed Web of Science ®Google Scholar
• Powers GD, Abbas AK, Miller RA. Frequencies of IL-2 and IL-4-secreting T cells in native and antigen-stimulated lymphocyte populations. J Immunol 1988; 140: 3352–3357
   PubMed Web of Science ®Google Scholar
• Burke F, Stuart-Naylor M, Davies B, Bulkwill F. The cytokine wall-chart. Immunol Today 1993; 14: 165–170
   PubMedGoogle Scholar
• Caruso C, Candore G, Cigna D, Colucci AT, Bongiardina C, Gervasi F, Manno M, Tantillo G. The HLA-B8, DR3 haplotype affects lymphocyte blood levels
   Google Scholar
• Ilonen J, Salonen Hyypia T, Lankinen K, Karttunen R, Salmi A. Immune functions in healthy blood donors with HLA-Dw2 and -Dw3 antigens. Immunobiology 1986; 171: 388–399
   PubMedGoogle Scholar
• Abb J, Zander H, Abb H, Albert E, Deinhardt F. Assocation of human leucocyte low responsiveness to inducers of interferon alpha with HLA-DR2. Immunology 1983; 49: 239–243
   PubMedGoogle Scholar
• Endres S, Cannon JG, Ghorbani R, Dempsey RA, Sisson SD, Lonnemann G, van der Meer JWM, Wolff SM, Dinarello CA. In vitro prodction of IL-1β, IL-1α, TNF and IL-2 in healthy subjects: distribution, effect of cyclooxygen-ase inhibition and evidence of independent gene regulation. Eur J Immunol 1989; 19: 2327–2333
   PubMed Web of Science ®Google Scholar
• Caruso C, Bcllina L. B8, DR3 antigens and production of human leucocyte migration inhibitory factor (LIF) by mononuclear cell stimulated with Concanavalin A (Con-A). Tissue Antigens 1983; 22: 167–169
   PubMedGoogle Scholar
• Crumpton MJ. HLA in medicine. Br Med Bull 1987; 43: 1–245
   PubMedGoogle Scholar
• Hansen JA, Nelson JL. Autoimmune diseases and HLA. Critical Rev Immunol 1990; 4: 307–328
   Google Scholar
• Moller G. HLA and disease susceptibility. Immunol Rev 1983; 70: 1–218
   PubMedGoogle Scholar
• Lawley TJ, Hall RP, Fauci AS, Katz SI, Hamburger MI, Frank MM. Defective Fc-receptor fuctions assocated with the HLA-B8/DR3 haplotype. N Engl J Med 1981; 340: 185–192
   Google Scholar
• McCombs CC, Michalski JP, de Shazo R, Bozelka B, Lane JTL. Immune abormalities associated with HLA-B8: lymphocyte subsets and functional correlates. Clin Immunol Immunopathol 1986; 39: 112–120
   PubMedGoogle Scholar
• Osoba D, Falk J. HLA-B8 phenotype associated with an increased mixed leukocyte reaction. Immunogenlics 1986; 6: 425–432
   Google Scholar
• McCombs CC, Michalski JP. Lymphocyte abnormality associated with HLA-B8 in healthy young adults. J Exp Med 1982; 156: 936–941
   PubMed Web of Science ®Google Scholar
• Davey FR, Kurec AS, Dock NL, Hubbell C, Falen SW. Association of HLA-DR antigens with the autologous mixed lymphocyte reaction. Tissue Antigens 1984; 4: 98–106
   Google Scholar
• Kallenberg CGM, Klaassen RJL, Beelen GM, The TH. The HLA-B8, DR3 phenotype and the primary immune response. Din Immunol Immunopathol 1985; 34: 135–140
   PubMedGoogle Scholar
• Kallemberg CGM, Klaassen RJL, Westra J, Beelen JM, Ockhuizen T. Immunoglobulin genes HLA-B8, DR3 and immune responsiveness to primary, immunogen. and mitogens in normal, subjects. Clin Immunol Immunopathol 1988; 47: 333–342
   PubMedGoogle Scholar
• Alper CA, Kruskall MS, Marcus-Bagley D, Craven DE, Katz A, Brink SJ, Dienstag JL, Awdeh Z, Yunis EJ. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989; 321: 708–712
   PubMed Web of Science ®Google Scholar
• Colucci AT, Di Lorenzo G., Ingrassia A, Crescimanno G, Modica MA, Candore G, Caruso C. Blood antiphosholipid antibodies levels are influenced by age, sex and HLA-B8, DR3 phenotype. Exp Clin Immunogenet 1992; 9: 72–79
   PubMedGoogle Scholar
• Beach JF, Caillat-Zucman S. Genetics of autoimmune endocrine diseases. Spinger Semin Immunopathol 1993; 14: 239–252
   PubMedGoogle Scholar
• Caruso C, Candore G, Coucci AT, Cigna D, Modica MA, Tantillo G, Salerno A. Natural killer and lymphokine activated killer activity in HLA-B8, DR3 subjects. Human Immunol 1993; 38: 226–230
   PubMedGoogle Scholar
• Bloom BR, Salgame P, Diamond B. Revisiting and revising suppressor T cells. Immumol Today 1992; 13: 131–136
   PubMedGoogle Scholar
• Romagnani S. Induction of Thl and Th2 responses: a key role for the “natural” immune response?. Immunol Today 1992; 13: 379–381
   PubMedGoogle Scholar
• Talor E, Rose NR. Hypothesis: the aging paradox and autoimmune disease. Autoimmunity 1991; 8: 245–249
   PubMed Web of Science ®Google Scholar
• Tomer Y, Shoenfeld Y. Ageing and autoantibodies. Autoimmunity 1988; 1: 141–149
   PubMedGoogle Scholar
• Candore G, Di Lorenzo G., Caruso C, Modica MA, Colucci AT, Crescimanno G, Ingrassia A, Barbagallo-Sagiorgi G, Salerno A. The effect of age on mitogen responsive T cell precursors in human beings is completely restored by interleukin-2. Mech Ageing Dev 1992; 63: 297–307
   PubMedGoogle Scholar